TRIUMPH-1: LY3437943 (Retatrutide) Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight, With Knee Osteoarthritis Appendix (GOA1)

Phase 3, randomised, double-blind trial in obesity, Overweight and osteoarthritis (OA) comparing Retatrutide once weekly with Placebo once weekly (2 arms). Primary endpoints: Percent Change from Baseline in Body Weight and Change from Baseline in WOMAC Pain Subscale Score (GOA1 subset). Started Sep 2023; status: completed.